Animals from control group were randomly assigned to either the drug treatment (Vatalanib, n = 8) or the vehicle (n = 6). Animals from myeloablation group were randomly assigned to either the drug treatment (Vatalanib, n = 9) or the vehicle (n = 8). Animals from AMD3100 treated group were randomly assigned to either the drug treatment (Vatalanib, n = 6) or the vehicle (n = 6). Vatalanib (LC laboratories, Woburn, MA, USA) was prepared for oral administration using the vehicle (cremophor-EL: DMSO: PBS at 1:1:8) and was administered orally by gavage, once a day at a dose of 50 mg kg−1 per feeding for two weeks starting on day 8 following implantation of orthotopic GBM. Vehicle treated animals received vehicle (cremophor-EL: DMSO: PBS at 1:1:8) by oral gavage for two weeks starting on day 8 following implantation of tumor. Drug or vehicle administration started eight days after tumor implantation and continued for two weeks (5 days/week). On day 22 following tumor implantation, animals underwent in-vivo MRI followed by euthanasia and collection of brain tissue.
Vatalanib
Manufactured by LC Laboratories
Sourced in United States
Vatalanib is a selective tyrosine kinase inhibitor. It functions by inhibiting the activity of vascular endothelial growth factor receptors (VEGFR).
Automatically generated - may contain errors
Lab products found in correlation
Neocuproine, by Merck Group (1 mentions)
Nvp aew541, by Cayman Chemical (1 mentions)
Pd0325901, by Merck Group (1 mentions)
Sb431542, by Selleck Chemicals (1 mentions)
Afatinib, by LC Laboratories (1 mentions)
U0126, by LC Laboratories (1 mentions)
Aicar, by LC Laboratories (1 mentions)
Linsitinib, by LC Laboratories (1 mentions)
Regorafenib, by Selleck Chemicals (1 mentions)
Suramin, by Merck Group (1 mentions)
Flavopiridol, by Merck Group (1 mentions)
Cabozantinib, by Selleck Chemicals (1 mentions)
Sorafenib, by Merck Group (1 mentions)
Thalidomide, by Merck Group (1 mentions)
Tnp 470, by Merck Group (1 mentions)
Axitinib, by Selleck Chemicals (1 mentions)
Su5416, by Merck Group (1 mentions)
Paclitaxel, by Merck Group (1 mentions)
Pazopanib, by LC Laboratories (1 mentions)
Vandetanib, by LC Laboratories (1 mentions)
5 protocols using vatalanib
1
Vatalanib treatment on orthotopic GBM
2
Vatalanib and AMD3100 Assay Protocol
3
Egg Yolk-based Compound Screening Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For egg yolk feeding, chicken eggs were obtained from local grocery stores, and the yolk was separated and diluted to 5% by volume with 0.3× Danieau solution as previously described (26 (link)). All drugs were made in 1,000× stock solution and stored in light-protected Eppendorf tubes at −20°C. NBI-31772 (5 mmol/L; Sigma-Aldrich), linsitinib (10 mmol/L; LC laboratories), H-89 (10 mmol/L; LC laboratories), AICAR (100 mmol/L; LC laboratories), afatinib (10 mmol/L; LC laboratories), SB431542 (10 mmol/L; Selleckchem), DAPT (10 mmol/L; Sigma-Aldrich), SU5402 (15 mmol/L; Calbiochem and Tocris), neocuproine (10 mmol/L; Sigma-Aldrich), PD0325901 (10 mmol/L; Sigma-Aldrich), U0126 (10 mmol/L; LC laboratories), and TUDCA (0.5 mol/L; Calbiochem) were dissolved in DMSO at the indicated concentrations. NVP-AEW541 (10 mmol/L; Cayman Chemicals), vatalanib (10 mmol/L; LC Laboratories), and SAG (10 mmol/L; EMD Millipore) were dissolved in water. CyA (10 mmol/L; LC Laboratories) was dissolved in ethanol.
Induction of transgene expression of Kir6.2DN was performed as previously described (24 (link)). SU5402 was added after 16 h of the induction for an 8-h treatment.
Induction of transgene expression of Kir6.2DN was performed as previously described (24 (link)). SU5402 was added after 16 h of the induction for an 8-h treatment.
4
Evaluating Anti-Angiogenic Compounds
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The anti-angiogenic compounds SU5416, combretastatin, thalidomide, TNP-470, flavopiridol, suramin, paclitaxel, and sorafenib were purchased from Sigma-Aldrich Co. (St Louis, MO, USA); vatalanib, motesanib, pazopanib, tivozanib, and vandetanib were purchased from LC Laboratories (Woburn, MA, USA). Axitinib, cabozantinib, and regorafenib were purchased from Selleck Chemicals (Houston, TX, USA). All other chemicals used in this study were obtained from Sigma-Aldrich Co., unless mentioned otherwise.
5
Preparation and Characterization of HET0016 Formulation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HPßCD (2-hydroxy Propyl-β-Cyclodextrin) was purchased from Sigma-Aldrich (St. Louis, MO), cell culture media was from Thermo Scientific (Waltham, MA), and fetal bovine serum was purchased from Hyclone (Logan, Utah). HET0016 was made by Dr. Levedyeva in the Department of Chemistry, Augusta University with a purity of more than 97%, and was prepared for animal treatment according to our previously described method [8 (link)]. Additional information for HET0016 synthesis strategies is provided in the S1 File . Cell culture grade DMSO was purchased from Fischer Scientific (Pittsburg, PA). the complex of HET0016 plus HPßCD was made as per previous publication [8 (link)]. VEGFR2 tyrosine kinase inhibitor (Vatalanib) and colony-stimulating factor 1 receptor (CSF1R) inhibitor (GW2580) were purchased from LC Laboratories, Woburn, MA. SB225002 (CXCR2 inhibitor) was purchased from Selleckchem, Houston, TX. Navarixin was purchased from MedKoo bioscience Inc, Morrisville, NC. All flow antibodies are from Bio Legend, San Diego, CA. All antibodies for western blotting, immunohistochemistry, and immunofluorescence were purchased from Santa Cruz (total-CXCR2 and anti-GAPDH), R&D Systems (anti-hCXCR2), Thermo Scientific (anti-Laminin), and Sigma Aldrich (β-actin and FITC-conjugated tomato lectin). All culture media were purchased from Corning and GE Healthcare Life Sciences.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!